Pod Insights a16z Podcast a16z Podcast: Players and Paths for Healthcare Startups About this episode The creation of each new biotechnology enables a tool, a therapy, or a diagnostic: a molecule, a protein, an app, a platform. And the process underneath isn't just complex in the science and engineering of it, but in the go to market.
So who are the...
Transcript Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.
0:00 Speaker 00 Welcome to the A16Z Podcast. Today, we're having another of our hallway-style conversations. These episodes are based on videos that are also available on our YouTube channel, youtube.com/A16Zvideos. What's the path to success in the world of healthcare startups? BioTeam general partners Jorge Conde and Vijay Pandey discuss how founders need to adjust their plans for bringing a new drug, process, etc. to market, and how go-to-market models and players involved may differ depending on the product, be it a molecule, process, or platform.
0:31 Vijay Pande? Hey, we've got Vijay Pandey and Jorge Conde here, general partners at Andreessen Horowitz on the Biofund. So we've got lightning round today. So we're seeing all these forces of biology coming to computer science and computer science coming into biology. What's the lay of land of that?
0:44 Speaker 02 Well, I think, as we all know, healthcare is a very complicated landscape. So let's just take it at a very high level and then we can sort of dive in and go through the various players here. So if you're developing anything in the healthcare space, and let's just focus on human healthcare for a second to put a scope on this. Generally speaking, if you're going to develop a technology or a tool, you're going to develop something that's going to enable a drug or a therapy, or you're going to enable something that's going to enable the diagnostic to help detect disease. At a very high level, it's tools, therapies, and diagnostics. So let's assume that you're playing in that space.
1:19 Vijay Pande? And you're thinking quite generally, the therapy could be many different types of therapies. I guess we'll see.
1:24 Speaker 02 That's right. It could be a chemical, it could be a protein, it could be a cell, it could be a gene, it could be an app. So it could be many, many different things. But generally, for the most part, if you're going to do anything that's going into humans or going to affect how disease is treated and managed, you're going to have to go through a fairly straightforward process in terms of chronology, but it's very complex underneath. So you've got to, A, discover something that's relevant for human health, and that's sort of the R&D piece. If you're developing a therapy or a diagnostic, then you've got to convince the people that matter, in this case, the regulatory agencies, to allow you to put this or use this in humans. Then you've got to figure out how to get it paid for. Then you've got to figure out how to educate the healthcare system that this is valuable for patients.
2:10 Speaker 02 And then you got to figure out how to get patients to actually use it.
2:13 Vijay Pande? Right.
2:14 Speaker 02 So, you know, it's not easy and you know, the joke we have, this is not B to B, this is not B to C. It's much more complicated than that. And so, you know, when you sort of dig into that, who are the various players there? So some of them are pretty straightforward. You have the regulatory agencies. So if you want to develop something on the therapeutic side, you're going to have to do human clinical trials.
2:31 Vijay Pande? Right.
2:32 Speaker 02 If you want to develop a diagnostic, it's a slightly different path, right? If you wanted to make a diagnostic that is quite literally, you know, a little box to test something, you got to go to the FDA.
2:42 Vijay Pande? Or CLIA presumably?
2:44 Speaker 02 Yeah, so now that's different. So if you wanted to develop something that could be tested in the lab, fortunately, the FDA has made it such that you could do something called a laboratory derived test in a CLIA lab. And CLIA just means that you've passed sort of the basic processes that ensure that your, your lab runs a good process and that data is reproducible, et cetera, et cetera. So if you're going to do that, that's a less risky proposal.
3:06 Vijay Pande? Right.
3:07 Speaker 02 You develop, you set up your own lab and you can run tests. And as long as your processes are robust, the regulatory.
3:13 Vijay Pande? And we've seen diagnostic startups take this L D D CLIA approach and that seems to be very natural to begin.
3:18 Speaker 02 I think that's, I think it's a natural sort of initial approach. It's lower risk and lets you get to the market much, much more quickly. On the therapeutic side, I think it's much harder, right? Because you do have to go through the traditional phase one, two, three clinical trials. And before that, you have to prove that it works in, in tests and both, you know, in cells and then in animals. It's a very long process. But then the other path is that you can develop a tool or technology that you sell into the R and D, R and D industry itself, which is a really interesting go to market path if you have a very powerful technology, because it allows you to do a lot of things. Number one is you can figure out how to slice and dice this technology to sell to multiple players in a non-excessive way.
3:52 Vijay Pande? Right.
3:53 Speaker 02 Number two, the R and D industry in the US alone is like a $75 billion a year annual industry. So I mean, there is a lot of spend that goes into the space. And so that's another path you can take. So if I'm an entrepreneur in bio, one of the first things I would say is, do I want to make my own drugs or diagnostics? Or do I want to empower the industry to make better drugs and diagnostics? Those are two very different go to markets.
4:14 Vijay Pande? Yeah, although I would think, and I think we've seen it's, it's hard to break into that, right? I mean, because you've got to have a tool that really changes the game so much that they will give you some fraction of that 75 bill.
4:24 Speaker 02 I think that's exactly right. And this is where this concept of engineering is important because it allows you to essentially convince player A.
4:33 Speaker 02 To give you value and without you essentially locking out the ability to engage player B and C and D because if something is widely applicable and transformative, usually you can essentially sell it again and again.
4:43 Vijay Pande? Is there any example of like a tools company that became like a huge thing?
4:46 Speaker 02 Uh, sure. I mean, there are many examples. Um, I think one of the classic examples is a company called Atomab that essentially came up with a better way to design monoclonal antibodies. And so what they were able to show is by partnering with virtually every company that is trying to develop monoclonal antibodies as a drug, as a therapy, they could take a small piece upfront. Once it proves that it works, they get a big piece of the economics on the backend. And they've shown this again and again and again. They're still a private company and last I heard it valued well north of a billion dollars.
5:17 Vijay Pande? Right.
5:18 Speaker 02 So they are a private biotech unicorn that's become that doing just that.
5:21 Vijay Pande? Yeah. And I guess, you know, to some degree, Illumina is an example as well, to the extent that it's driving research spend in addition to other areas in genomics.
5:28 Speaker 02 I think Illumina is a wonderful example, right? Because they basically took what was an impossible concept of being able to sequence, you know, full genomes at scale, cheaply and reliably, quickly, um, and made it not only possible, but made themselves um, sort of necessary to do this. You can't do genomics essentially without Illumina.
5:47 Vijay Pande? So, you know, just, I think we're running out of time. I mean, so, you know, how would you sort of think of the, this whole space together? What, how do you conceptualize it?
5:55 Speaker 02 So the way I conceptualize it is it all comes down to, you know, your go to market should be dependent on your technology, right? So if you have a technology that's very broadly applicable in, for example, diagnosing disease, the LDT path makes a lot of sense because you can start to churn out tests as you sort of develop them. If you've got a platform that allows you to develop drugs in a way that weren't, was not possible, maybe going and becoming your own drug development company might be the way to go. If you have a platform that's so broadly applicable at sort of elucidating disease biology, then doing that the partnership route might be the way to go because you'll never develop sort of the deep domain expertise in every single disease in parallel.
6:33 Vijay Pande? Right. Yeah, I can imagine it, especially for, you know, a lot of tech heavy founder style, as a product style founders, that just understanding the go to market issues from the very beginning, I think would be very important in how they define and shape the company and shape the product.
6:47 Speaker 02 I think that's exactly right. So the way I would think about this as an entrepreneur is do I understand what I need to prove, how I'm going to get it approved, and who's going to pay for it? And that will help define your go to market.
6:57 Vijay Pande? Perfect. Well, I think we're out of time.
6:59 Speaker 02 Thank you.
Previous Pande & Conde: When (and How) Biology Becomes Engineering Next a16z Podcast: On Recent Consolidation in the Healthcare Industry Page updated September 30, 2026 · transcript and summary are machine-generated